A case-based clinical framework for navigating benzodiazepine prescribing in the grey zones of outpatient practice, including inherited prescriptions, tapering, PRN use, withdrawal, co-use risk, and harm-reduction decisions. Includes practical teaching, real-world cases, and point-of-care clinical tools.
In this Grey Zone case, we follow a patient with opioid use disorder who is becoming more stable on buprenorphine but continues buying pressed “Xanax bars” to manage anxiety and prevent withdrawal. The central question is whether replacing an unpredictable street supply with a known, structured benzodiazepine prescription can reduce overall harm. We work through …
In this Grey Zone case, we look at PRN benzodiazepine prescribing when the medication is still helping the patient function, but the number of situations where it feels necessary has gradually begun to expand. The central question is not whether a particular pill count is inherently safe or unsafe. It is whether the medication is …
In this Grey Zone case, we look at a different problem: a patient who has taken a stable benzodiazepine dose responsibly for many years, but whose overall clinical picture has changed enough that continuing the same dose indefinitely no longer feels like the safest plan. The case follows a clinician-initiated taper that the patient did …
In this first Grey Zone case, we work through a common outpatient dilemma: inheriting a patient who has taken a standing benzodiazepine regimen for years and is worried that a new clinician is going to take it away. Using a patient taking long-term alprazolam, we look at how to stabilize first, understand what the medication …
Read more “Case 1 — Inheriting a Chronic Benzodiazepine Prescription”
In this final section of the Core Framework, we focus on how to approach benzodiazepine tapering without making discontinuation itself more important than the patient’s safety or ability to function. We work through taper pace, direct tapers versus medication switches, increasingly small reductions at lower doses, difficult symptoms during tapering, and the circumstances where a …
Read more “Core Framework Section 5 — Tapering & Harm Reduction”
In this section of the Core Framework, we move from pharmacology and withdrawal into the practical decisions involved in prescribing benzodiazepines in outpatient care. The focus is on setting a clear clinical frame, distinguishing intermittent from standing use, treating the underlying disorder, and adjusting the approach when benzodiazepines intersect with age, pregnancy, trauma, substance use, …
Read more “Core Framework Section 4 — Prescribing in Practice”
In this section of the Core Framework, we focus on the clinical risks that become most important with regular benzodiazepine exposure, especially physical dependence and withdrawal. We distinguish dependence from misuse and benzodiazepine use disorder, review how withdrawal can present, and look at the often difficult task of separating withdrawal, rebound symptoms, and recurrence of …
Read more “Core Framework Section 3 — Dependence & Withdrawal”
In this section of the Core Framework, we focus on the pharmacologic differences between benzodiazepines that actually matter in clinical practice: onset, duration, potency and equivalence, metabolism, and how those properties shape prescribing decisions. We also look at why some benzodiazepines are more reinforcing, why some are more likely to produce peaks, troughs, or interdose …
In this first section of the Core Framework, we start with the central tension in benzodiazepine prescribing: these medications can provide unusually rapid and meaningful relief, while also creating risks and responsibilities that can persist long after the original prescription. We also introduce the approach used throughout Benzodiazepines in the Grey Zone: where the evidence …